Skip to main content
AVIR logo

Atea Pharmaceuticals, Inc.

AVIRNASDAQHealthcareBiotechnology

$4.16Today:- (-)1Y +26.96%

As of Oct 26, 2026 close

Market cap
$333.01M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.87$6.45
Volume (live)
-
Avg. volume (3M)
303.83K

Atea Pharmaceuticals (AVIR) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Atea Pharmaceuticals used $132.03M of cash in operating activities. Free cash flow was −$132.03M. It repurchased $25.52M of its own shares.

Atea Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Atea Pharmaceuticals, Inc. (AVIR) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-158.35-168.39-135.96-115.91121.19-10.95-14.03-9.06
Depreciation & Amortization0.420.420.420.260.030.020.020.02
Deferred Income Tax-6.360.00-48.560.00-29.390.00-0.500.00
Stock Based Compensation20.7251.7749.4346.7239.627.460.620.41
Change in Working Capital16.48-7.4816.16-46.59-247.85300.210.580.73
Change in Accounts Receivable0.000.000.000.000.00-5.820.000.00
Change in Accounts Payable8.490.211.70-1.9810.29-0.490.16-0.09
Change in Other Working Capital8.005.741.80-44.60-0.64306.510.420.82
Other Operating Activities-4.94-11.82-15.45-5.4729.390.000.500.54
Net Cash from Operating Activities-132.03-135.50-85.40-120.98-87.01296.73-12.81-7.91
Investing Activities
Capital Expenditures0.000.000.00-1.940.00-0.030.00-0.01
Acquisitions0.000.000.000.450.000.000.000.00
Purchases of Investments-281.94-461.18-562.36-545.350.000.000.000.00
Sales/Maturities of Investments470.73517.28602.6791.890.000.000.000.00
Other Investing Activities0.000.000.00-0.450.000.000.000.00
Net Cash from Investing Activities188.7956.1140.30-455.410.00-0.030.00-0.01
Financing Activities
Common Stock Issued0.060.270.260.231.47317.63-0.020.12
Common Stock Repurchased-25.520.000.000.000.000.000.000.00
Other Financing Activities-0.490.000.000.140.00214.120.0054.84
Net Cash from Financing Activities-25.750.270.260.371.47531.75-0.0227.48
Summary
Net Change in Cash31.02-79.13-44.84-576.02-85.54828.46-12.8319.56
Cash at Beginning of Period64.70143.82188.66764.68850.2221.7734.6015.04
Cash at End of Period95.7164.70143.82188.66764.68850.2221.7734.60
Free Cash Flow-132.03-135.50-85.40-122.93-87.01296.71-12.82-7.92

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Atea Pharmaceuticals Cash Flow

What is Atea Pharmaceuticals's free cash flow?

Atea Pharmaceuticals had negative free cash flow of $132.03M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Atea Pharmaceuticals pay dividends or buy back shares?

Yes. In fiscal 2025 Atea Pharmaceuticals returned $25.52M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition